Home›Trial›NCT06958315

NCT06958315RECRUITING

Inclisiran (Leqvio®) in Patients With Atherosclerotic Vascular Disease and/or Heterozygous Familial Hypercholesterolemia Treated in Spain: the INSPIRE Study

Study Summary

This study aims to address several key questions regarding the use of inclisiran in real-world clinical practice in Spain.

Conditions

Atherosclerotic Vascular Disease Heterozygous Familial Hypercholesterolemia

Interventions / Drugs

View on ClinicalTrials.gov ↗

Sponsor

Diversified Pharma

Study Details

Enrollment200 participants

Primary Completion—

Lead SponsorNovartis Pharmaceuticals

Data Retrieved2026-04-11 02:55:49.151804+00:00

What This Trial Means for Biotech Investors

Trial Phase Context

Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 200 participants

Sponsor Catalyst Profile

Novartis AG (NVS) is the sponsoring company for this trial. BiotechSign currently grades this company D (36/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

NVS Full Pipeline →All Companies →

Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.